Clinical

Dataset Information

0

A Phase 2 study of concurrent combination therapy of TFTD (TAS-102) and bevacizumab in patients of more than 70 years of age with unresectable, advanced/recurrent colorectal cancer (KSCC 1602)


ABSTRACT: Interventions: TFTD 35 mg/m2, po, bid at day 1-5 and day 8-12 and bevacizumab 5mg/kg, iv, every 2 weeks are concurrently administered. The administration is continued until the meeting of discontinuation criteria as 1 course of 28 days. Primary outcome(s): Progression-Free Survival Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2640480 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2615810 | ecrin-mdr-crc
| S-EPMC4366220 | biostudies-literature
| S-EPMC5536260 | biostudies-literature
| 2306310 | ecrin-mdr-crc
| S-EPMC7394338 | biostudies-literature
| S-EPMC8122404 | biostudies-literature
| S-EPMC4062790 | biostudies-other
| 2650700 | ecrin-mdr-crc
| S-EPMC3783404 | biostudies-literature
| S-EPMC2745631 | biostudies-literature